실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

9,268+프로그램
35+FDA 승인
4,079+모집 중
ADC 1068·Antibody 5456·CGT 2744차세대 추천 →·Data Tier →
9268프로그램35FDA 승인
2오늘 방문
554누적 방문
8122갱신 대기S–CData TierS/A/B차세대1068HER2 breast5456Antibody2744CGT→Psoriasis→NSCLC35FDA 승인
피드Data Tier차세대

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · Ebglyss혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

최근 활동

RSS →

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
다음 갱신 D-14 · 마지막 7월 13일
AntibodyHotRocheatApproved

Bevacizumab (Bevacizumab)

Colorectal Neoplasms · Recurrent Platinum-Sensitive Fallopian T

#RecurrentPlatinum-SensitiveFallo#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1131상태 RECRUITING
AntibodyHotRochevedotin, rituximab, cycloph…Approved

rituximab (rituximab)

Rheumatic Disease · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1091상태 DISCONTINUED
AntibodySHOTFDACuratedFDABiologicMerckvedotin plus pembrolizumab …Approved

pembrolizumab (Keytruda)

Multiple solid tumors · PD-1

#PD-1#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 100%임상시험 1334상태 APPROVED
AntibodyHotRochederuxtecan (Dato-DXd, Datro…Approved

trastuzumab (Herceptin)

Non Small Cell Lung Cancer; Colorectal Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#Antibody#Approved#인기#항체+5
효능 ORR 91.8%임상시험 676상태 RECRUITING
AntibodyHotEli LillyreleaseApproved

Cetuximab (Cetuximab)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 757상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 648상태 RECRUITING
AntibodySHOTFDACuratedFDABiologicAbbVieApproved

adalimumab (Humira, Hyrimoz, Amjevita)

Rheumatoid arthritis, psoriasis, Crohn's disease, ulcerative colitis, axial SpA · TNF-α

#TNF-#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 98.85%임상시험 420상태 APPROVED
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 413상태 ACTIVE
AntibodySHOTFDACuratedFDABiologicJanssenApproved

daratumumab (Darzalex)

Multiple myeloma · CD38

#CD38#Antibody#Approved#FDA승인#바이오모아추천+5
효능 ORR 97%임상시험 342상태 APPROVED
ADCSHotBiologicImmunityBio, Inc.Phase 3

Nab-paclitaxel (Nab-paclitaxel)

Triple Negative Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 69.1%임상시험 216상태 RECRUITING
ADCSHOTFDACuratedFDABiologicDaiichi SankyoDXd (topo-I inhibitor)Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

HER2+ breast cancer, HER2-low, gastric · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 79.7%임상시험 215상태 APPROVED
AntibodyAHotAstraZenecaderuxtecan 3Phase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#인기#항체+5
효능 ORR 84.6%임상시험 181상태 RECRUITING
ADCSHOTFDACuratedFDABiologicRocheMMAE (maytansinoid)Approved

ado-trastuzumab emtansine (Kadcyla, T-DM1, ado-trastuzumab emtansine / T-DM1)

HER2+ breast cancer · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 80%임상시험 159상태 APPROVED
ADCSHOTFDACuratedFDABiologicRemeGenMMAEApproved

disitamab vedotin (Disitamab Vedotin, RC48)

HER2+ urothelial, gastric, breast · HER2

#HER2#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 50%임상시험 146상태 ACTIVE
ADCAHotBiologicBeOne MedicinesPhase 3

5-FU (5-FU)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 85%임상시험 143상태 RECRUITING
ADCAHotBiologicCellerant TherapeuticsVedotin Therapy]Phase 3

Filgrastim (Filgrastim)

Male Breast Cancer; Stage II Breast Cancer · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88%임상시험 142상태 RECRUITING
ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 70.3%임상시험 136상태 RECRUITING
ADCCHotBiologicKosei Hasegawa, MD, PhDatPhase 3

Olaparib (Olaparib)

Carcinoma, Ovarian Epithelial · Ovary Cancer

#OvaryCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 70.3%임상시험 135상태 DISCONTINUED
ADCAHotBiologicChia Tai Tianqing Pharmaceutica…Phase 3

Capecitabine/Paclitaxel/Albumin Paclitaxel (Chemotherapy drug, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel))

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+2
효능 ORR 60.4%임상시험 133상태 RECRUITING
ADCAHotBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Approved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Colorectal Cancer; Resectable Colorectal Carcinoma · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 71.7%임상시험 123상태 RECRUITING
ADCBHotBiologicNCIC Clinical Trials Groupvedotin, 120 mg intr…Phase 3

Epirubicin (Epirubicin)

Breast Cancer · HER2

#HER2#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 62.7%임상시험 108상태 RECRUITING
ADCABiologicJanssen Research & Development,…Phase 3

Osimertinib (Osimertinib)

Carcinoma, Non-Small-Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 76.7%임상시험 88상태 RECRUITING
ADCSFDAFDABiologicRochevedotin, rituximab, cycloph…Phase 3

Polatuzumab Vedotin (Polatuzumab Vedotin)

Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma · FRα

#FR#ADC#Phase3#FDA승인#인기+5
효능 ORR 100%임상시험 80상태 RECRUITING
AntibodyARochederuxtecan (Dato-DXd, Datro…Phase 3

Herceptin (Trastuzumab, Trastuzumab (Herceptin))

Breast Neoplasm, Exercise · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.2%임상시험 80상태 RECRUITING
ADCAHOTFDACuratedFDABiologicGSKMMAFApproved

belantamab mafodotin (Blenrep, GSK2857916)

Multiple myeloma · BCMA

#BCMA#ADC#Approved#FDA승인#바이오모아추천+5
효능 ORR 57%임상시험 76상태 DISCONTINUED

1 / 167 페이지

← 이전다음 →
전체 9,268개 프로그램 보기